DEF: National Research Corporation Announces 2025 Annual Meeting and New Omnibus Incentive Plan

National Research Corporation (NRC Health) is set to hold its Annual Meeting of Shareholders on May 7, 2025, featuring proposals including the election of directors, ratification of the accounting firm, executive compensation approval, and the approval of a new Omnibus Incentive Plan.

Summary

• National Research Corporation (NRC Health) will hold its Annual Meeting of Shareholders on May 7, 2025.
• Shareholders will vote on several proposals, including the election of two directors, ratification of KPMG LLP as the independent accounting firm, and approval of executive compensation.
• A key proposal is the approval of the National Research Corporation 2025 Omnibus Incentive Plan, designed to attract, motivate, and retain employees through equity compensation.
• The company had 22,785,421 shares of Common Stock outstanding and entitled to vote as of March 20, 2025.
• The board recommends voting for the election of directors, ratification of KPMG, approval of executive compensation, and approval of the Omnibus Incentive Plan.
• Trent Green has been appointed as the new Chief Executive Officer, effective June 1, 2025, and Michael Hays will transition to the role of Chairman.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative elements. The introduction of a new CEO and incentive plan are positive, but the lack of bonus payouts and executive departures temper the overall sentiment.

Positives

• The proposed 2025 Omnibus Incentive Plan is designed to align executive compensation with shareholder interests.
• The appointment of Trent Green as CEO is expected to bring significant healthcare leadership experience to the company.
• The board is committed to good corporate governance, including independent directors and a majority vote policy.
• The company has a clawback policy in place to recover incentive-based compensation in certain circumstances.
• The company offers a 401(k) plan and other benefits to assist associates in preparing financially for retirement.

Negatives

• The company's TRCV as of December 31, 2024, was below the threshold, resulting in no bonuses being earned under the 2024 Short-Term Cash Plan.
• Some executive officers have left the company, including Kevin Karas, Jason Hahn, Christophe Louvion, and Linda Stacy.
• The company's CEO compensation is significantly below the median level paid to chief executive officers of companies of similar size.

Risks

• Failure to obtain shareholder approval for the 2025 Omnibus Incentive Plan could limit the company's ability to attract and retain talent.
• Changes in the healthcare industry and regulatory environment could impact the company's performance.
• The company's reliance on key personnel could pose a risk if they were to leave or become unable to perform their duties.
• The company's compensation policies and practices could create incentives for excessive risk-taking.
• The company's stock price could be negatively impacted by factors beyond its control, such as economic conditions or market sentiment.

Future Outlook

The company aims to align executive compensation with shareholder interests through equity-based awards and performance-based incentives. The appointment of a new CEO and the implementation of a new strategic plan are expected to drive future growth.

Management Comments

• The Compensation Committee believes the shares of Common Stock remaining under 2006 Equity Plan and the 2004 Director Stock Plan (together, the Predecessor Plans) are insufficient to fulfill the Companys objectives.
• The Compensation Committee believes the 2025 Omnibus Incentive Plan is needed to (i) recruit talent to fill open positions on our management team as they arise and (ii) continue to make equity-based awards to Participants, which tie a portion of total compensation to equity awards and align with stockholder interests.

Industry Context

The announcement reflects a common practice in publicly traded companies to use equity-based compensation to align executive interests with those of shareholders. The focus on healthcare leadership experience in the new CEO appointment aligns with industry trends.

Comparison to Industry Standards

• The document mentions that Mr. Hays' salary and overall compensation are significantly below the median level paid to chief executive officers of companies of similar size.
• The document mentions that the company considered the competitiveness of pay levels against similarly sized companies, executive compensation design issues, market trends and technical considerations.
• The document mentions that the company does not use a peer group given the absence of any publicly traded peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Impacted by decisions on director elections, executive compensation, and the new incentive plan.
• Employees: Affected by the new incentive plan and changes in executive leadership.
• Customers: Indirectly impacted by the company's ability to attract and retain talent and execute its strategic plan.

Next Steps

• Shareholders to vote on proposals at the Annual Meeting on May 7, 2025.
• Trent Green to assume the role of CEO on June 1, 2025.
• Implementation of the National Research Corporation 2025 Omnibus Incentive Plan, pending shareholder approval.

Key Dates

Keywords

Omnibus Incentive Plan, Executive Compensation, Annual Meeting, Board of Directors, Shareholders, Directors, NRC Health, KPMG, Stock